Table 2.

Adverse events.

Subjects with adverse event, n (%)	G-CSF	PEG-G-CSF	p
Any AE during mobilization*  AE leading to discontinuation Serious AE after mobilization Hematological malignancies after mobilization Most common AEs during mobilization Bone pain  Grade 1–2 Grade 3–4 Headache  Grade 1–2  Grade 3–4 Injection site reaction  Grade 1–2  Grade 3–4 Flu-like symptoms  Grade 1–2  Grade 3–4	49 (92.5) 0 (0.0) 0 (0.0) 0 (0.0) 40 (75.5) 33 (62.3) 7 (13.2) 21 (39.6) 16 (30.2) 5 (9.4) 48 (90.6) 48 (90.6) 0 (0.0) 4 (7.5) 2 (3.8) 2 (3.8)	72 (86.7) 0 (0.0) 0 (0.0) 0 (0.0) 65 (78.3) 50 (60.2) 15 (18.1) 31 (37.3) 21 (25.3) 9 (10.8) 66 (79.5) 66 (79.5) 0 (0.0) 7 (8.4) 5 (6.0) 2 (2.4)	0.300 - - - 0.700 0.814 0.452 0.790 0.532 0.792 0.088 0.088 - 0.853 0.562 0.646

*Adverse events (AEs) that started between the first administration of granulocyte-colony-stimulating factor (G-CSF) and 30 days thereafter were regarded as events that occurred “during” the mobilization period.